Lipocine closed at $1.44 on Nov 4, down 1.37%, within 0.0% of its 52-week closing low. Volume of 108.1K shares was 0.02× its 20-day average (below normal).
Split-adjusted performance: -31.4% over one month, -40.7% over six months, -45.7% over one year.
Short interest was 351.4K shares at the Oct 15 settlement, up 259.3% from the prior report (4.6% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| LPCNLipocine | $1.44 | −1.37% | −40.7% | −100.0% | — | — | $11.9M | |
| BIVIBioVie | $1.34 | −22.54% | −19.3% | — | — | — | $11.6M | Compare |
| CLRBCellectar Biosciences INC NEW | $1.23 | −6.11% | −65.2% | — | — | — | $11.6M | Compare |
| HINDVyome Holdings | $1.74 | −1.93% | −21.1% | — | −2543.3% | — | $12.2M | Compare |
| TVRDTvardi Therapeutics | $0.8614 | +3.17% | −76.5% | — | — | — | $11.5M | Compare |
| LSTALisata Therapeutics | $1.06 | −2.75% | −67.5% | −100.0% | — | — | $11.5M | Compare |
| AEONAEON Biopharma | $0.2086 | −1.70% | −77.0% | — | — | — | $12.3M | Compare |
| RKTORocket One | $0.4422 | −4.33% | — | — | — | — | $11.0M | Compare |
| DAREDare Bioscience | $0.6619 | +1.83% | −79.1% | — | −1590.4% | — | $13.0M | Compare |
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
